StoneX Group Inc. Takes Position in Tempus AI, Inc. (NASDAQ:TEM)

StoneX Group Inc. purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,615 shares of the company's stock, valued at approximately $527,000.

A number of other large investors have also recently added to or reduced their stakes in TEM. The Manufacturers Life Insurance Company lifted its position in shares of Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company's stock valued at $1,686,000 after buying an additional 2,765 shares during the last quarter. Captrust Financial Advisors acquired a new stake in Tempus AI during the 3rd quarter valued at $2,726,000. Benjamin Edwards Inc. bought a new position in Tempus AI during the third quarter worth $725,000. Stifel Financial Corp acquired a new position in shares of Tempus AI in the third quarter valued at $218,000. Finally, Kovitz Investment Group Partners LLC acquired a new stake in shares of Tempus AI during the 3rd quarter worth about $1,367,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on TEM shares. TD Cowen reissued a "buy" rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Needham & Company LLC boosted their price target on Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Piper Sandler decreased their price objective on Tempus AI from $70.00 to $55.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, William Blair reissued a "market perform" rating on shares of Tempus AI in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Tempus AI currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.18.

Remove Ads

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 3,240,234 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the transaction, the chief executive officer now owns 4,895,589 shares of the company's stock, valued at approximately $287,615,853.75. The trade was a 39.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew Polovin sold 13,135 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total transaction of $603,947.30. Following the completion of the transaction, the executive vice president now directly owns 154,171 shares of the company's stock, valued at $7,088,782.58. This trade represents a 7.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,601,969 shares of company stock valued at $317,330,782.

Tempus AI Price Performance

TEM traded down $3.59 on Friday, hitting $42.58. 11,548,799 shares of the stock were exchanged, compared to its average volume of 5,329,092. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The business has a 50-day moving average of $58.45 and a two-hundred day moving average of $51.51.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.